AVALO THERAPEUTICS, INC. Paid-in-Kind Interest
AVALO THERAPEUTICS, INC. (AVTX) reported Paid-in-Kind Interest of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2020-03-11
- AVALO THERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2019-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2019-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for fiscal 2018 was $302.88K, a 1387.34% increase from fiscal 2017.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for fiscal 2017 was $20.36K, a 87.45% decline from fiscal 2016.
- AVALO THERAPEUTICS, INC. paid-in-kind interest for fiscal 2016 was $162.27K, a 44.76% decline from fiscal 2015.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | -$24.34K derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | -$24.34K derived: sum of 3 quarters · filed 2020-03-11 | -$48.68K derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | -$24.34K derived: sum of 2 quarters · filed 2020-03-11 | -$48.68K derived: sum of 3 quarters · filed 2020-03-11 | $197.43K derived: sum of 4 quarters · filed 2020-03-11 |
| 2018-12-31 | -$24.34K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$48.68K derived: sum of 2 quarters · filed 2020-03-11 | $197.43K derived: sum of 3 quarters · filed 2020-03-11 | $302.88K 10-K · filed 2020-03-11 |
| 2018-09-30 | -$24.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $221.77K derived: sum of 2 quarters · filed 2019-11-14 | $327.22K 10-Q · filed 2019-11-14 | $327.22K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $246.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $351.57K 10-Q · filed 2019-08-08 | $351.56K derived: sum of 3 quarters · filed 2019-08-08 | $350.58K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $105.45K 10-Q · filed 2019-05-09 | $105.45K derived: sum of 2 quarters · filed 2019-05-09 | $104.46K derived: sum of 3 quarters · filed 2019-05-09 | $112.43K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$988.00 derived: sum of 2 quarters · filed 2019-03-18 | $6.97K derived: sum of 3 quarters · filed 2019-03-18 | $20.36K 10-K · filed 2019-03-18 |
| 2017-09-30 | -$987.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $6.98K derived: sum of 2 quarters · filed 2018-11-13 | $20.36K 10-Q · filed 2018-11-13 | $48.54K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $7.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $21.35K 10-Q · filed 2018-08-09 | $49.53K derived: sum of 3 quarters · filed 2018-08-09 | $86.47K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $13.39K 10-Q · filed 2018-05-11 | $41.56K derived: sum of 2 quarters · filed 2018-05-11 | $78.51K derived: sum of 3 quarters · filed 2018-05-11 | $123.54K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $28.17K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $65.12K derived: sum of 2 quarters · filed 2018-04-02 | $110.15K derived: sum of 3 quarters · filed 2018-04-02 | $162.27K 10-K · filed 2018-04-02 |
| 2016-09-30 | $36.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $81.98K derived: sum of 2 quarters · filed 2017-11-07 | $134.10K 10-Q · filed 2017-11-07 | $223.09K derived: sum of 4 quarters · filed 2018-04-02 |
| 2016-06-30 | $45.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $97.15K 10-Q · filed 2017-08-14 | $186.14K derived: sum of 3 quarters · filed 2018-04-02 | $299.09K derived: sum of 4 quarters · filed 2018-04-02 |
| 2016-03-31 | $52.12K 10-Q · filed 2017-05-09 | $141.11K derived: sum of 2 quarters · filed 2018-04-02 | $254.06K derived: sum of 3 quarters · filed 2018-04-02 | $276.42K derived: sum of 4 quarters · filed 2018-04-02 |
| 2015-12-31 | $88.99K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $201.94K derived: sum of 2 quarters · filed 2018-04-02 | $224.30K derived: sum of 3 quarters · filed 2018-04-02 | $293.75K 10-K · filed 2018-04-02 |
| 2015-09-30 | $112.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $135.31K derived: sum of 2 quarters · filed 2016-11-08 | $204.76K 10-Q · filed 2016-11-08 | $249.05K derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $22.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $91.81K 10-Q · filed 2016-08-15 | $136.10K derived: sum of 3 quarters · filed 2017-03-14 | |
| 2015-03-31 | $69.44K 10-Q · filed 2016-05-16 | $113.74K derived: sum of 2 quarters · filed 2017-03-14 | ||
| 2014-12-31 | $44.29K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $989.26K 10-K · filed 2017-03-14 | ||
| 2014-09-30 | $944.97K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |